ARCH:TSXV ACHFF:OTC
  • Home
  • About usOur story, our approach
  • Our Science Pipeline, research & publications
    • Our Key Platforms
      • MetaBlok™Treating, organ injury caused by inflammation
      • AB569Treatment for Respiratory Pseudomonas aeruginosa Infections
      • BORGPeptide Solid Surface Interface
      • MetaMx™Brain Tumor Initiating Cell Targeting
    • Our PublicationsPeer-reviewed scientific publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team Management & lead scientists
    • Our ManagementGovernance, Executive, Board of Directors and Advisors
    • Our Principal ScientistsLearn about the scientists behind our technologies
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub Investor relations, fundamentals
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us

Reports and Filings

  • Uncategorised
    Article Count:  9
  • Our Science

    Our portfolio approach gives us the freedom to pursue a wider range of technologies, maximizing opportunities for growth and value creation. We develop new medical innovations we believe can make a significant clinical impact in improving the health of patients.

    • Our portfolio covers a range of technologies that focus on different therapeutic areas, which helps us to mitigate risk and create and build value.
    • Our scientists collaborate in a way that facilitates knowledge sharing across different technologies and therapeutic areas.
    Article Count:  0
    • Our Key Platforms
      Article Count:  4
    • Our Publications
      Article Count:  0
      • Brain Tumor Stem Cell Targeting
        Article Count:  2
      • Borg Peptide Solid Surface Interface
        Article Count:  5
      • Treatments for Inflammation
        Article Count:  5
      • AB569
        Article Count:  4
  • Our Team

    We have the expertise to advance and build value in our technologies from discovery to commercialization.

    • Our management team and Board of Directors have significant experience bringing technologies to human trial.
    • We also engage industry experts and consultancies to ensure we bring best-in-class talent and experience to advance and build value in our technologies. 
    Article Count:  0
    • Our Principal Scientists
      Article Count:  4
    • Our Management
      Article Count:  1
  • Investor Hub

    We are ruthless in our evaluation of preclinical technologies, focusing on opportunities that have the potential to meet unmet medical needs and present a short path to value creation; we only pursue the best.

    • We follow a rigorous screening process to evaluate our investments in preclinical technologies. 
    • We only pursue the technologies that meet our strict criteria, which includes a strong intellectual property position and commercial potential. 
    • We only invest when we are certain the technologies meet our criteria.
    • We are focused on developing intellectual property and future revenue through patent filings and technology ownership.
    Article Count:  0
    • Fundamentals
      Article Count:  2
      • Press Releases
        Article Count:  5
        • Press Releases 2011
          Article Count:  11
        • Press Releases 2012
          Article Count:  7
        • Press Releases 2013
          Article Count:  8
        • Press Releases 2014
          Article Count:  8
        • Press Releases 2015
          Article Count:  15
        • Press Releases 2016
          Article Count:  12
        • Press Releases 2017
          Article Count:  13
        • Press Releases 2018
          Article Count:  14
        • Press Releases 2019
          Article Count:  9
        • Press Releases 2020
          Article Count:  29
    • Reports and Filings
      Article Count:  5

Recent News

March 4th 2021

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

Read More
February 26th 2021

Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Read More
Arch Biopartners
  • Home
  • About us
  • Our Science
    • Our Key Platforms
    • Our Publications
  • Our Team
    • Our Management
    • Our Principal Scientists
  • Investor Hub
    • Fundamentals
    • Reports and Filings
  • Contact Us
Contact us
+1 647 428 7031
info@archbiopartners.com
Mailing Address
27 St. Clair Ave East
P.O. Box 305
Toronto, Ontario
Canada M4T 2M5
Copyright Arch BioPartners 2020. All Rights Reserved. Legal notices.
PAGE TOP | TYPE SIZE | | RESET
Reports and Filings
  • Home
  • About us
  • Our Science
    • Our Key Platforms
      • MetaBlok™
      • AB569
      • BORG
      • MetaMx™
    • Our Publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team
    • Our Management
    • Our Principal Scientists
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us